Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive TKI Therapy in Advanced Thyroid Cancer
NCT03630120Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib, sorafenib, cabozantinib and vandetanib in differentiated thyroid cancer (DTC) and Medullary Thyroid Cancer (MTC) (4 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Progressive Disease at 2 years, Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Intolerability at 2 years and 1 more. Started Aug 2018; status: terminated.
02
Drugs
lenvatinibsorafenibcabozantinibvandetanib
03
Conditions
differentiated thyroid cancer (DTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT03630120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630120.